Sensei Biotherapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Sensei Biotherapeutics, Inc. (SNSE) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-30.16-34.10-48.59-36.79-20.10
Depreciation & Amortization1.321.351.350.690.21
Stock Based Compensation3.144.455.815.661.49
Change in Working Capital-0.49-4.331.01-0.72-0.40
Change in Accounts Payable-0.45-2.332.02-1.430.34
Change in Other Working Capital1.551.361.190.06-0.73
Other Operating Activities1.551.361.196.301.09
Net Cash from Operating Activities-24.67-32.02-39.03-30.26-17.71
Investing Activities
Capital Expenditures-0.15-0.18-0.322.03-1.21
Acquisitions0.000.000.000.00-0.20
Purchases of Investments-44.60-21.15-46.87-183.670.00
Sales/Maturities of Investments67.1859.5897.12-141.410.00
Net Cash from Investing Activities22.4438.4149.95-143.12-1.40
Financing Activities
Debt Repayment-0.81-0.76-0.63-0.260.00
Common Stock Issued0.030.050.34140.590.02
Common Stock Repurchased-0.01-10.380.000.000.00
Other Financing Activities-0.01-0.080.10140.42-2.11
Net Cash from Financing Activities-0.79-11.17-0.29163.9435.45
Summary
Net Change in Cash-3.02-4.7810.64-9.4416.35
Cash at Beginning of Period13.0117.807.1616.600.00
Cash at End of Period9.9913.0117.8016.600.00
Free Cash Flow-24.82-32.20-39.35-31.97-18.91